deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02717195

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (DayBreak)

Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Sponsor: H. Lundbeck A/S

Conditions Schizophrenia
Interventions Lu AF35700 Olanzapine Risperidone
Updated 21 times since 2017 Last updated: Oct 30, 2019 Started: Apr 30, 2016 Primary completion: Aug 30, 2018 Completion: Oct 8, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02717195, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by H. Lundbeck A/S, it has been updated 21 times since 2016, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Dec 2019 · 12 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 8 months · monthly snapshot

Change History

21 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 16 earlier versions

  1. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE3

  2. Dec 2018 — Dec 2019 [monthly]

    Completed PHASE3

  3. Nov 2018 — Dec 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  7. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Dec 2017 — May 2018 [monthly]

    Recruiting PHASE3

  9. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  10. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  11. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  12. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  13. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  14. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  15. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • H. Lundbeck A/S
Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Atlanta, United States , Austin, United States , Barcelona, Spain , Belgrade, Serbia , Bellflower, United States , Berlin, United States , Bełchatów, Poland , Bialystok, Poland , Bradenton, United States and 101 more locations